Amgen (AMGN)
Develops and manufactures medicines and biosimilars across general medicine, rare disease, inflammation, and oncology.
$401.35
vs last close+8.19 (+2.08%)
Something off on this page? Send us feedback.
Next report
Nov 3, 26
in 42 days
EPS estimate
$5.79
Revenue estimate
$10.05B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26Apr '26Aug '26Nov '26
Reported$5.31$4.90$6.02$5.64$5.29$5.15$6.29Pending
Estimate$5.04$4.27$5.28$5.02$4.73$4.77$5.62$5.79
Surprise+5.4%+14.8%+14.0%+12.4%+11.8%+8.0%+11.9%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26Apr '26Aug '26Nov '26
Reported$9.09B$8.15B$9.17B$9.56B$9.87B$8.62B$10.05BPending
Estimate$8.88B$8.06B$8.94B$8.97B$9.47B$8.58B$9.43B$10.05B
Surprise+2.3%+1.1%+2.6%+6.6%+4.1%+0.5%+6.7%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $6.34 | — | — |
| Sep 2028 | $6.44 | — | — |
| Jun 2028 | $6.60 | — | — |
| Mar 2028 | $5.83 | — | — |
| Dec 2027 | $6.37 | — | — |
| Sep 2027 | $6.15 | — | — |
| Jun 2027 | $6.27 | — | — |
| Mar 2027 | $5.42 | — | — |
| Dec 2026 | $5.80 | — | — |
| Nov 2026 | $5.79 | — | — |
| Aug 2026 | $5.62 | $6.29 | +11.9% |
| Apr 2026 | $4.77 | $5.15 | +8.0% |
| Feb 2026 | $4.73 | $5.29 | +11.8% |
| Nov 2025 | $5.02 | $5.64 | +12.4% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Aug 2023 | |||
| Apr 2023 | |||
| Jan 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Jan 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Jan 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Feb 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Feb 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Jan 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $6.34 | — | — | $10.58B | — | — | — |
| Sep 2028 | $6.44 | — | — | $10.31B | — | — | — |
| Jun 2028 | $6.60 | — | — | $10.22B | — | — | — |
| Mar 2028 | $5.83 | — | — | $9.38B | — | — | — |
| Dec 2027 | $6.37 | — | — | $10.56B | — | — | — |
| Sep 2027 | $6.15 | — | — | $10.16B | — | — | — |
| Jun 2027 | $6.27 | — | — | $10.24B | — | — | — |
| Mar 2027 | $5.42 | — | — | $9.03B | — | — | — |
| Dec 2026 | $5.80 | — | — | $10.25B | — | — | — |
| Nov 3, 2026 | $5.79 | — | — | $10.05B | — | — | — |
| Aug 4, 2026 | $5.62 | $6.29 | +11.9% | $9.43B | $10.05B | +6.7% | +4.6% |
| Apr 30, 2026 | $4.77 | $5.15 | +8.0% | $8.58B | $8.62B | +0.5% | −4.8% |
| Feb 3, 2026 | $4.73 | $5.29 | +11.8% | $9.47B | $9.87B | +4.1% | +8.2% |
| Nov 4, 2025 | $5.02 | $5.64 | +12.4% | $8.97B | $9.56B | +6.6% | +7.8% |
| Aug 5, 2025 | |||||||
| May 1, 2025 | |||||||
| Feb 4, 2025 | |||||||
| Oct 30, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 2, 2024 | |||||||
| Feb 6, 2024 | |||||||
| Oct 31, 2023 | |||||||
| Aug 3, 2023 | |||||||
| Apr 27, 2023 | |||||||
| Jan 31, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| Apr 27, 2022 | |||||||
| Feb 7, 2022 | |||||||
| Nov 2, 2021 | |||||||
| Aug 3, 2021 | |||||||
| Apr 27, 2021 | |||||||
| Feb 2, 2021 | |||||||
| Oct 28, 2020 | |||||||
| Jul 28, 2020 | |||||||
| Apr 30, 2020 | |||||||
| Jan 30, 2020 | |||||||
| Oct 29, 2019 | |||||||
| Jul 30, 2019 | |||||||
| Apr 30, 2019 | |||||||
| Jan 29, 2019 | |||||||
| Oct 30, 2018 | |||||||
| Jul 26, 2018 | |||||||
| Apr 24, 2018 | |||||||
| Feb 1, 2018 | |||||||
| Oct 25, 2017 | |||||||
| Jul 25, 2017 | |||||||
| Apr 26, 2017 | |||||||
| Feb 2, 2017 | |||||||
| Oct 27, 2016 | |||||||
| Jul 27, 2016 | |||||||
| Apr 28, 2016 | |||||||
| Jan 28, 2016 | |||||||
| Oct 28, 2015 | |||||||
| Jul 30, 2015 |